An interim Japanese pediatric surveillance study reported no lisdexamfetamine dependence- or abuse-related events. That observation does not demonstrate that such events are impossible or that risk is zero in all settings.
The prospective observational study enrolled children and adolescents aged six to under 18 receiving lisdexamfetamine in routine care. At the interim cutoff, 1819 had enrolled, case-report forms were collected for 1012, and 1006 contributed to safety analyses. Effectiveness analyses included 916. These denominators describe different stages of data availability and should not be exchanged.
Decreased appetite was the most frequently reported adverse drug reaction. Insomnia, nausea, weight decrease and other reactions were also recorded, and eight serious reactions occurred in five patients. No dependence- or abuse-related events were reported in the interim data. Symptom scores improved over observation, but without a control group that pattern cannot isolate treatment effects from other care, selection or time.
Routine clinical surveillance can detect outcomes beyond a tightly managed trial, yet depends on reporting, follow-up and data collection. Treating physicians varied in assessments, and not every enrolled patient had contributed a completed report at cutoff. A zero-event observation must therefore retain its population, reporting system and observation period. It should not be generalized to misuse, different ages or unmonitored exposure. The paper supports ongoing safety monitoring rather than an assurance of absence of all harm. It is also an interim report, not final results from every planned follow-up year.
See long-term cognitive observations and the limits of an uncontrolled design.